Document is current
Any future updates will be listed below
-
Authors
Azar, Pouya
Li, Victor W.
Nikoo, Mohammadali
LaBranche, Jennifer
Wong, James S. H.
Machado, Jessica
To, Tam
Hawamdeh, Alaa Al
Ignaszewski, Martha J.
Herring, Andrew A.
Vogel, Marc
Kehoe, Laura
Raheemullah, Amer
Fitzgerald, Ruchi
Krausz, Reinhard M.
Montaner, Julio S. G.
Maharaj, Anil R.
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 26 February 2026
First Online: 13 March 2026
Declarations
:
: The study protocol was approved by theClinical Research Ethics Board at the University of British Columbia(H23-02262).
: Not applicable.
: Not applicable.
: PA was a consultant on Indivior-led buprenorphine extended-release studies (terminated in 2023) and receives honoraria for presentations organized by Indivior, which are unrelated to this case series. He has received research funding from Vancouver Coastal Health Research Institute, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada Research Coordinating Committee, University of British Columbia, and VGH & UBC Hospital Foundation. JM has received honoraria for educational presentations organized by Indivior, which are unrelated to this cases series. MJI has received honorarium for educational presentations organized by Indivior and research funding from Vancouver Coastal Health Research Institute and UBC. JGSM has received financial support to his institution from the BC Ministry of Health, Health Canada, Canadian Institutes of Health Research, Public Health Agency of Canada, Genome Canada, Genome BC, Vancouver Coastal Health, VGH & UBC Hospital Foundation, Gilead Sciences, Janssen, Merck Sharp & Dohme, and ViiV Healthcare. All other co-authors report no conflicts of interest.
